Activation of innate immunity has direct effects in modulating viral replication, tumor growth, angiogenesis, and inflammatory and other immunological processes. It is now established that unmodified siRNA can activate this innate immune response and therefore there is real potential for siRNA to elicit nonspecific therapeutic effects in a wide range of disease models. Here we demonstrate that in a murine model of influenza infection, the antiviral activity of siRNA is due primarily to immune stimulation elicited by the active siRNA duplexes and is not the result of therapeutic RNA interference (RNAi) as previously reported. We show that the misinterpretation stems from the use of a particular control green fluorescent protein (GFP) siRNA that we identify as having unusually low immunostimulatory activity compared with the active anti-influenza siRNA. Curiously, this GFP siRNA has served as a negative control for a surprising number of groups reporting therapeutic effects of siRNA. The inert immunologic profile of the GFP sequence was unique among a broad panel of published siRNAs, all of which could elicit significant interferon induction from primary immune cells. This panel included eight active siRNAs against viral, angiogenic, and oncologic targets, the reported therapeutic efficacy of which was based on comparison with the nonimmunostimulatory GFP siRNA. These results emphasize the need for researchers to anticipate, monitor, and adequately control for siRNA-mediated immune stimulation and calls into question the interpretation of numerous published reports of therapeutic RNAi in vivo. The use of chemically modified siRNA with minimal immunostimulatory capacity will help to delineate more accurately the mechanism of action underlying such studies.
Introduction

M
ANY GROUPS HAVE REPORTED on the therapeutic effects of synthetic short interfering RNA (siRNA) in a wide array of animal models for human disease (reviewed in Behlke, 2006) . More recently, it has also been shown that siRNAs are capable of activating the mammalian immune response, primarily through endosomal activation of the Tolllike receptor-7/8 (TLR7/8) pathway, resulting in induction of interferons (IFNs) and inflammatory cytokines from innate immune cells (Hornung et al., 2005; Judge et al., 2005) . Measurable cytokine production via siRNA can be eliminated by the selective incorporation of 2Ј-O-methyl (2ЈOMe) nucleotides, in particular guanosine or uridine residues, into the constituent RNA oligonucleotides (Judge et al., 2006; and reviewed in Judge and MacLachlan, 2008) . More recently, naked siRNA has been shown to activate TLR3 on the surface of vascular endothelial cells and to trigger the release of IFN-␥ and interleukin (IL)-12 that mediate nonspecific antiangiogenic effects in vivo (Kleinman et al., 2008) . Unlike the RNA-induced TLR7/8 response, it has been reported that the activation of cell surface TLR3 by naked siRNA is not inhibited by 2ЈOMe modification (Kleinman et al., 2008) .
The potential influence of siRNA-mediated immune responses on key readouts of therapeutic efficacy is a critical consideration when designing and interpreting in vivo RNA interference (RNAi) studies. However, surprisingly few of the reported studies have adequately tested, or controlled, for the potential effects of siRNA-mediated immune stimulation, making the many published claims of therapeutic efficacy a collective liability for the RNAi field that remains to be addressed. When the potential for immune stimulation has been examined and deemed to be negative, common deficiencies in study design include (1) the use of nonresponsive cell lines that cannot recapitulate the immune response elicited by professional immune cells; (2) assay time points that likely miss the rapid and transient induction of cytokines; (3) testing for only one class of cytokine to conclude a lack of response; and (4) the selective testing of only one siRNA sequence (either active or control, not both) for immunostimulatory potential (reviewed in Judge and MacLachlan, 2008) .
Of the few studies to control for immune stimulation, Morrissey and coworkers (2005) showed that modification of siRNA prevents off-target inhibition of virus infection in a hepatitis B virus (HBV) model in vivo. These authors used an inverted siRNA control and showed that this siRNA control was immunostimulatory and capable of nonspecifically inhibiting HBV in vivo. Chemical modification of the inverted control siRNA abrogated observed off-target effects in vivo. Despite this published report in a viral model, it is apparent from the literature that unmodified (and therefore potentially immunostimulatory) siRNAs are still used in the majority of in vivo RNAi studies.
Anti-influenza efficacy of siRNA in vivo has been reported by two groups (Ge et al., 2004; Tompkins et al., 2004) . Ge and coworkers (2004) examined IFN-␣ protein in lungs of mice 24 hr postinjection of siRNA-PEI polyplex and showed that there was no IFN-␣ induction in their model 24 hr postinjection. It is likely that these authors missed the appropriate time point to measure IFN-␣ in this model. Interestingly, the control used in these studies was a commonly used siRNA targeting green fluorescent protein (GFP). Several other studies have also used this same GFP control siRNA to draw conclusions about the specificity of observed therapeutic effects with active siRNA against a range of targets in vivo (e.g., Zender et al., 2003; Flynn et al., 2004; Song et al., 2005; Palliser et al., 2006 UUGGAAUUGAUUGCGAAAG Palliser et al. (2006) largely responsible for the reduction of viral titer after treatment with the active anti-influenza siRNA. Misinterpretation of this potent therapeutic effect with respect to its specificity comes from the striking observation that the widely used GFP control siRNA has remarkably low immunostimulatory capabilities. This is illustrated by our observations that the GFP siRNA is unique in its inability to elicit a robust immune response when compared with an additional panel of 15 published sequences including a number of active siRNAs reported to show therapeutic efficacy relative to the GFP control in models of cancer, neoangiogenesis, and viral infection.
Materials and Methods
siRNAs
siRNAs used in these studies were synthesized by the University of Calgary (Calgary, AB, Canada), Dharmacon (Lafayette, CO), or Integrated DNA Technologies (Coralville, IA) and were received as desalted, deprotected oligonucleotides. All native and 2ЈOMe-modified RNA sequences are listed in Table 1 . In some studies, siRNAs were encapsulated into cationic lipid particles by a process of spontaneous vesicle formation followed by dialysis as previously described .
PEI polyplex formation with siRNAs
siRNA polyplexes were formed with an in vivo jetPEI transfection reagent (Polyplus-transfection, New York, NY), according to the methods used by Ge and coworkers (2004) , at an N/P ratio of 5 (the N/P ratio refers to the number of nitrogen residues of jetPEI per DNA phosphate). Briefly, PEI (0.12 mg/ml) and siRNA (1.2 mg/ml) were diluted in 5% glucose water (5DW). The PEI was then added to the siRNA, vortexed, and incubated for 15 min at room temperature. Polyplexes were formed immediately before injection into mice.
In vitro immune stimulation assays
Human peripheral blood mononuclear cells (PBMCs) were isolated from the whole blood of healthy donors by a standard Ficoll-Hypaque density centrifugation technique. Immune stimulation assays were performed as previously described (Judge et al., 2006) . In brief, PBMCs were resuspended in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and plated in 96-well plates at 2.5 ϫ 10 5 cells per well. Lipid-encapsulated or PEI-polyplexed siRNA were immediately added to cells and cultured for 24 hr. IFN-␣ was measured in culture supernatants by enzymelinked immunosorbent assay (ELISA) (PBL Biomedical Laboratories, Piscataway, NJ)
In vitro anti-influenza RNA interference assay
The Madin-Darby canine kidney (MDCK) cell line was obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated FBS and 1% penicillin-streptomycin (Pen-Strep). Tissue culture-adapted influenza A/PR/8/34 (PR8, subtype H1N1) was obtained from the ATCC. MDCK cells were seeded at 8000 cells per well (100 l/well) in a 96-well plate for a cell density, 24 hr later, of 50% confluency. siRNA complexes were made with Lipofectamine 2000 (LF2000; Invitrogen, Carlsbad, CA) according to the manufacturer's instructions at a ratio of 1 g of siRNA to 4 l of LF2000 in Opti-MEM I medium (Invitrogen). Transfections were performed with 10 l of siRNA complex per well in complete medium without antibiotics. Five hours after siRNA addition, medium was removed and cells were washed with phosphate-buffered saline (PBS). A 1:800 dilution of influenza A/PR/8/34 stock was added at 50 l/well in virus infection medium (DMEM, 0.3% bovine serum albumin [BSA] , and 10 mM HEPES). After 1.5 hr, virus was removed and 200 l of virus growth medium (DMEM, 0.3% BSA, 10 mM HEPES, and tolylsulfonyl phenylalanyl chloromethyl ketone [TPCK]-modified trypsin (0.25 g/ml; MJS-BioLynx, Brockville, ON, Canada) was added to the cells and incubated for 48 hr at 35°C. Supernatants were harvested and stored at Ϫ80°C until a hemagglutinin (HA) ELISA were performed according to the manufacturer's instructions (Takara Bio, Otsu, Shiga, Japan). and hemagglutinin (HA) in supernatants assessed at 24 hr by ELISA (mean ϩ SD triplicate cultures). Percent viral inhibition relative to LF2000 alone is shown.
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Animal studies
Animal studies were completed in accordance with the Canadian Council on Animal Care guidelines after approval had been obtained from the local Animal Care and Use Committee at Protiva Biotherapeutics (Burnaby, BC, Canada). Sixto 8-week-old female BALB/c mice were subjected to a 1-week quarantine and acclimation period before use. siRNA formulations were administered by standard intravenous injection in the lateral tail vein in 0.2 ml of PBS or 5DW. To measure in vivo cytokine induction, blood was collected by cardiac puncture 6 hr after siRNA administration and processed as plasma for cytokine analysis. In some studies, lung tissues were also collected into RNAlater solution (Sigma-Aldrich, St. Louis, MO) for mRNA analysis.
In vivo influenza model
All manipulations of virus and virus-infected mice were carried out in a biological safety cabinet. The antiviral efficacy of active and control siRNAs was determined according to Ge and coworkers (2004) in an experimental model of influenza A infection in BALB/c mice. siRNA formulations were administered intravenously as a single dose of 80-120 g. Four hours later, animals were challenged intranasally with mouseadapted influenza A strain PR/8/34 (Charles River Laboratories, Wilmington, MA) in 0.05 ml of saline (a 1:40,000 dilution of virus stock). Lungs were harvested 48 hr after virus inoculation and processed by grinding in either PBS for determination of log 10 tissue culture infectious dose (TCID 50 ) assay (see below) or in lysis buffer for HA enzyme immunoassay (EIA) according to the manufacturer's instructions (Takara Bio).
MDCK-hemagglutinin assay of lung viral titers
Frozen lungs were homogenized in a FastPrep tissue homogenizer (MP Biomedicals, Solon, OH), placed on ice for 1 min, and then subjected to a second round of homogenization. Lung lysates were centrifuged at 3000 rpm for 10 min in a refrigerated Eppendorf benchtop centrifuge and then placed on ice. Lung lysates were diluted in DMEM-5 medium (DMEM-5% FBS plus 1% Pen-Strep antibiotics and 1% [2 mM final] L-glutamine) in 96-well flat-bottom plates. Ten microliters of lung lysate was added to 90 l of medium and 10-fold serial dilutions were made in the plate (10 -1 to 10 -7 dilutions). Influenza A/PR/8/34 (tissue culture adapted; from the ATCC) was diluted similarly in 10-fold serial dilutions starting with 10 l of stock virus and used as a positive control in the assay. MDCK cells were trypsinized and diluted to 1.5 ϫ 10 5 cells/ml in DMEM-5 medium and added to the diluted virus and lysates at 1.5 ϫ 10 4 cells per well in the 96-well plates (100 l/well of cells added to 100 l of diluted virus). Cells were incubated overnight at 35°C. Cells were then washed with PBS and cultured in virus growth medium without BSA (DMEM, 10 mM HEPES, 2 mM L-glutamine, 1% Pen-Strep and 0.25 g/ml TPCK modified trypsin) for 4 days. Supernatants were then transferred to 96-well round-bottom plates and 50 l of fresh 1% chicken red blood cells (Charles River Laboratories) in PBS was added and incubated at room temperature for 1 hr, followed by scoring for agglutination. Viral titers were determined by interpolation of the dilution end point that gave hemagglutination in 50% of wells (Ge et al., 2004) . Viral titers are shown as TCID 50 values. The Student t test was performed as indicated.
Cytokine ELISA
All cytokines were quantified with sandwich ELISA kits according to the manufacturer's instructions. These were mouse or human IFN-␣ (PBL Biomedical Laboratories), and mouse or human IL-6 (eBioscience, San Diego, CA).
Measurement of IFIT1 mRNA in mouse lung
Murine lungs were homogenized in tissue and lysis solution (EPICENTRE Biotechnologies, Madison, WI) containing proteinase K (50 mg/ml; EPICENTRE Biotechnologies) in a FastPrep tissue homogenizer. Tissues were homogenized three times at a speed of 5.5 for 15 sec each, followed by incubation in a 65°C water bath for 15 min. Lysates were centrifuged for 5 min at 16,000 ϫ g at 16°C to clarify. The QuantiGene assay (Panomics, Fremont, CA) was performed as per the manufacturer's instructions (QuantiGene 1.0 manual) to quantitate induction of interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) mRNA relative to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in lung lysates. The IFIT1 probe set was specific to mouse IFIT1 (positions 4-499, NM_008331) and the GAPDH probe set was specific to mouse GAPDH (positions 9-319, NM_008084). Data are shown as the ratio of IFIT1 relative light units (RLU) to GAPDH RLU.
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FIG. 2. 2ЈOMe-modified anti-influenza siRNAs show no antiviral efficacy in vivo.
Viral load in the lungs of influenza A PR/8/34-infected mice after intravenous administration of (A) native or 2ЈOMe NP/PA siRNA cocktail (120 g of PEI-complexed siRNA per mouse) and (B) nontargeting native siRNA (100 g of lipid-encapsulated ApoB MM siRNA per mouse). Data reflect three separate experiments measuring either HA units (A and B, solid columns) or infectious viral titers by TCID 50 (B, stippled columns) 48 hr after viral infection. Both active and nontargeting native (immunostimulatory) siRNA elicited significant viral knockdown. Data represent mean ϩ SD, n ϭ 4 mice per group.
Results
Anti-influenza 2ЈOMe siRNAs do not induce detectable IFN-␣ but do maintain in vitro antiviral efficacy
Unmodified siRNA sequences have an inherent capacity to be immunostimulatory to some degree (Heil et al., 2004; Hornung et al., 2005; Judge et al., 2005; Sioud, 2005; Diebold et al., 2006) . A straightforward method of abrogating unwanted immune stimulation is to incorporate 2Ј-O-methyl (2ЈOMe)-uridine or -guanosine residues in the sense strand of an siRNA duplex (Judge et al., 2006) . We applied this approach to design nonimmunostimulatory siRNAs targeting the nucleoprotein (NP) and polymerase (PA) genes of influenza A virus, using siRNA sequences previously described as efficacious in a murine model of influenza (Ge et al., 2003 (Ge et al., , 2004 Tompkins et al., 2004) . Native (unmodified) NP and PA siRNAs induced significant levels of IFN-␣ in mice when administered in a lipidic delivery vehicle whereas the 2ЈOMe-modified variants of these siRNAs induced no detectable IFN-␣ (Fig. 1A) , demonstrating their significantly reduced capacity to activate an innate immune response. Consistent with our previous studies (Judge et al., 2006) , the 2ЈOMe siRNAs retained the ability to mediate RNAi in vitro, as demonstrated by the equipotent inhibition of influenza A (strain PR/8/34) viral replication in MDCK cells by both native and 2ЈOMe NP1496 siRNAs (Fig. 1B) .
Modified anti-influenza siRNAs show no antiviral efficacy in vivo
We used the influenza A/PR/8/34 model in BALB/c mice to confirm the therapeutic efficacy of these siRNAs in vivo. As reported (Ge et al., 2004) , administration of a cocktail of native NP1496 and PA2087 siRNAs in PEI complexes before inoculation with influenza A/PR/8/34 significantly reduced viral levels in the lung 48 hr after infection ( Fig. 2A) . Surprisingly however, treatment with the corresponding 2ЈOMe siRNA cocktail had no measurable effect on viral load ( Fig.  2A) . Because the 2ЈOMe siRNAs retain antiviral activity in vitro, in a culture system devoid of responsive immune cell types, this finding implied that the antiviral activity of the native influenza siRNA in vivo was primarily the result of
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FIG. 3.
Control GFP siRNA has unusually weak immunostimulatory activity compared with active anti-influenza siRNA.
(A) IFN-␣ induction by lipid-encapsulated NP1496 and GFP949 siRNA in human PBMC cultures. Native or 2ЈOMe (-mU) siRNA were cultured with PBMCS for 24 hr at 0.1-9 g/ml. Native GFP949 siRNA induced no detectable IFN-␣ in culture supernatants (representative of at least two separate experiments; mean ϩ SD of triplicate cultures; lower limit of quantitation, 15 pg/ml). (B) Plasma IFN-␣ and (C) IFIT1 mRNA upregulation in the lung, 6 hr after intravenous administration of 120 g of PEI-complexed GFP949 or NP1496 siRNA or 5% glucose water (5DW) vehicle control. Native GFP949 induced no detectable plasma IFN-␣ and only weak IFIT1 mRNA induction compared with native NP1496 siRNA (mean ϩ SD; n ϭthe immune response induced by the unmodified siRNAs. Treatment of mice with a nontargeting control siRNA, ApoB-MM (Judge et al., 2006) , that displayed comparable immunostimulatory activity to the native influenza siRNA (Fig.  1A) confirmed that siRNA-mediated immune stimulation alone has significant inhibitory effects on influenza viral replication in this model, as assessed by both hemagglutinin (HA) units and infectious viral titer (TCID 50 ) in the lung (Fig.  2B ).
Control GFP siRNA is less immunostimulatory than active anti-influenza siRNA
The in vivo efficacy of anti-influenza siRNA was originally reported by two separate groups (Ge et al., 2004; Tompkins et al., 2004) , both using the same nontargeting GFP-949 siRNA to draw their conclusions. Strikingly, when we tested this sequence for immunostimulatory activity, neither the native nor the 2ЈOMe GFP-949 siRNA elicited a detectable cytokine response from human PBMC cultures when formulated in lipid particles. By comparison, native NP1496 siRNA provoked a strong, dose-dependent IFN-␣ response (Fig. 3A) . A similar discrepancy in the immunostimulatory profiles of these active and control sequences was apparent in vivo after intravenous administration of PEI-complexed siRNA. Unlike NP1496, native GFP-949 siRNA induced no detectable increase in plasma IFN-␣ levels in mice, even at the therapeutic dosing levels (120 g) used in the influenza model (Fig. 3B) . The magnitude of any local IFN signaling in the lungs was assessed by measuring IFIT1 mRNA expression 6 hr after siRNA administration. Native GFP-949 induced weak but detectable upregulation of IFIT1 expression in the lung that was abrogated when the 2ЈOMe siRNA variant was used (Fig. 3C) . In contrast, native NP1496 induced strong IFIT1 upregulation that was 6-fold higher than with native GFP-949, confirming that the control siRNA sequence has a relatively low capacity to activate an IFN response in vivo. IFIT1 induction was also abolished in 2ЈOMe NP1496 siRNA-treated mice, further demonstrating the utility of this approach for generating nonimmunostimulatory siRNA. It has been reported that naked 21-mer siRNA, including 2ЈOMe siRNA, can also activate an immune response in vivo via TLR3 on the cell surface (Kleinman et al., 2008) . Because IFIT1 is not only strongly induced by the actions of IFNs (Der et al., 1998; Geiss et al., 2001 ) but also directly via activation of dsRNA receptors including TLR3 (Sarkar et al., 2003) , the lack of IFIT1 induction implies that there was no significant activation of either the TLR7/8 or TLR3 pathway in the lung by PEI-complexed 2ЈOMe siRNA.
Degree of immune stimulation correlates with anti-influenza effects in vivo
When GFP-949-treated mice were challenged with influenza A virus there was a slight but not significant effect on infectious viral titers in the lung (Fig. 4) . In agreement with our initial results (Fig. 1C) , only pretreatment with native NP1496 siRNA demonstrated significant antiviral effects, whereas 2ЈOMe NP1496 showed only slight reductions of viral titer that were not statistically significant (Fig. 4) . There was no reduction in viral titer with the control modified GFP-mU siRNA (Fig. 4) . These studies support our interpretation that the therapeutic effects of siRNA in this viral model directly correlate with the degree of immune stimulation and interferon activity induced by the siRNA in the lung, whereby the less stimulatory GFP-949 is less effective at reducing influenza titer than the immunostimulatory NP1496 siRNA. The differential in viral titer reduction between NP-mU and NP1496 highlights the contribution of immune stimulation to viral inhibition in the influenza A model.
Active unmodified siRNAs are more immunostimulatory than GFP control siRNA used in these studies
In reviewing the literature reporting therapeutic effects of native siRNA in vivo we have found that a surprising number of studies have used the same GFP siRNA (containing either 3Ј-UU, -dTdT, or -CC overhangs) as a nontargeting control (Reich et al., 2003; Song et al., 2003 Song et al., , 2005 Flynn et al., 2004; Ge et al., 2004; Hamar et al., 2004; Kishida et al., 2004; Tompkins et al., 2004; Lomas-Neira et al., 2005; Perl et al., 2005; Thomas et al., 2005; Wesche-Soldato et al., 2005; Palliser et al., 2006) . None of these reports adequately address the question of immune stimulation by the active and control siRNA. To better appreciate the spectrum of immunostimulatory activity within native siRNA, EGFP (GFP containing 3Ј-CC overhangs in the sense strand) was tested alongside a panel of 14 previously described active or control sequences (see Table 1 ) to assess their relative ability to activate an immune response. This panel included eight active siRNAs, the therapeutic efficacy of which has been reported on the basis of comparison with the EGFP control siRNA (Reich et al., 2003; Song et al., 2003 Song et al., , 2005 Flynn et al., 2004; Hamar et al., 2004; Perl et al., 2005; Wesche-Soldato et al., 2005; Palliser et al., 2006) . Of all the siRNAs tested, EGFP was unique in its inability to induce detectable levels of IFN-␣ from primary immune cells (Fig. 5A) . These findings are consistent with our observations that conventionally designed native siRNA sequences can stimulate the innate immune response and serves to highlight the highly unusual prop-
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FIG. 4.
The degree of immune stimulation correlates with anti-influenza effects in vivo. Shown are viral titers (log TCID 50 ) in the lungs of GFP or NP1496 siRNA-treated mice after influenza A PR/8/34 infection. Experiments were conducted as in Fig. 1 . Only Native NP1496 siRNA caused significant viral inhibition (mean ϩ SD; n ϭ 4 mice; p ϭ 0.003).
erties of the GFP siRNA sequence. It is important to note that two other commonly used controls, the Qiagen siRNA control and Luc siRNA control were moderate in their IFN-␣ induction (Fig. 5A ), being either more or less immunostimulatory than their comparative active siRNAs, depending on sequence.
An exhaustive study demonstrating that naked siRNA can elicit nonspecific antiangiogenic effects through engagement of TLR3 has cast doubt on the mechanism of action underlying a number of clinical studies using siRNAs targeting the vascular endothelial growth factor (VEGF) pathway (Kleinman et al., 2008) . However, because this TLR3 activation was reported to be independent of both siRNA sequence and chemistry, it is unclear how this nonspecific therapeutic effect would manifest itself in preclinical studies that employed nontargeting control siRNA. We noted that the primary report of VEGF siRNA activity in a murine model of ocular neovascularization (Reich et al., 2003) was one such study that had used the nonimmunostimulatory GFP siRNA under our investigation. As expected, the murine VEGF siRNA used by Reich and coworkers (2003) , and also by Song and coworkers (2005) , induced high IFN-␣ secretion from primary immune cells when administered in a lipidic delivery vehicle whereas the corresponding GFP control siRNA was nonstimulatory (Fig. 5B) . It should be clarified that, unlike the clinical development of naked VEGF siRNA, the murine angiogenesis model reported by Reich and coworkers (2003) used a lipid vehicle in complex with siRNA for intraocular delivery. It is possible therefore that the difference in antiangiogenic activity observed between unmodified VEGF and GFP control siRNAs in this model may be a result of their differential effects on activating immune cells via intracellular TLR7, rather than through the indiscriminate activation of surface TLR3 on endothelial cells by naked siRNA. Further studies using chemically modified, nonimmunostimulatory VEGF siRNA, in concert with methods that detect the specific mRNA cleavage product predicted by an RNAi mechanism of action, are required to confirm the specificity of therapeutic effects in such models. Table 1 . Data represent mean (pg/ml) IFN-␣ ϩ SD in supernatants after 24 hr culture with lipid-encapsulated siRNA (1 g/ml) and are representative of at least two separate experiments.
Discussion
tion, tumor growth, angiogenesis, inflammation, and other immunological processes. To avoid the potential of misinterpreting therapeutic efficacy caused by siRNA-mediated immune stimulation for a specific RNAi effect in animal models, it is critical that researchers appreciate the capacity of siRNAs to activate such a response and to fully characterize the immunostimulatory potential of both active and control siRNA sequences. Our findings that a widely used control siRNA sequence shows minimal capacity to activate an IFN response compared with all other formulated siRNAs studied by our group provide a striking example in support of this requirement. These results are relevant to any study wherein there is a differential in immune stimulation between active and control siRNAs, for example, in vivo studies in which formulated siRNAs can access immune cells and differentially activate intracellular TLR7/8. This scenario can be avoided by the use of chemically modified siRNAs in conjunction with appropriate vehicles that enable the cytoplasmic delivery of siRNAs, without activating RNA-sensing immune receptors. It is not clear at present why the GFP siRNA sequence has such unusually low immunostimulatory capacity, or indeed how it has come to be used as a negative control in such a wide variety of in vivo RNAi studies, including several seminal papers describing the therapeutic application of siRNA (Reich et al., 2003; Song et al., 2003 Song et al., , 2005 Ge et al., 2004; Hamar et al., 2004; Tompkins et al., 2004; Palliser et al., 2006) . Surprisingly, none of these reports adequately addressed the potential for immune stimulation to affect the various biological readouts, either because of a complete lack of immunological testing or through inappropriate assay design such as the use of nonresponsive cell lines or assay time points that would fail to capture the transient cytokine/interferon response elicited by unmodified siRNA. Although the large majority of unmodified siRNAs can induce TLR7/8-mediated immune stimulation when administered by a variety of delivery vehicles, the rules governing this sequence-dependent effect appear to be broad. It has been proposed that the strength of TLR7 activation by RNA oligonucleotides is dictated by the number of uridine residues within the context of a native ribose sugar backbone (Diebold et al., 2006) and may also be influenced by GU-rich sequence motifs (Heil et al., 2004; Judge et al., 2005) . In this context, the GFP sequence has relatively few uridines (6 of 38 nucleotides that form the 19-bp duplex region) and a single GU dinucleotide in each strand. Our current understanding, however, is insufficient to make firm predictions based on sequence analysis and it remains an absolute requirement to empirically determine the immunostimulatory potential of any siRNA by formulating the duplex (e.g., in DOTAP, PEI, Lipofectamine, or a researcher's own proprietary delivery vehicle) and applying it to immune cells under appropriate assay conditions.
Using the murine influenza A infection model, we have been able to replicate the antiviral effects of particular siRNAs targeting the influenza NP and PA genes originally reported by two research groups (Ge et al., 2004; Tompkins et al., 2004) . However, through the use of nonimmunostimulatory 2ЈOMe-modified active siRNA variants and additional nontargeting immunostimulatory control duplexes, we have drawn the conclusion that the in vivo therapeutic activity of these anti-influenza siRNAs is due primarily to immune stimulation and not to specific RNAi in this model.
It is interesting that Ge and coworkers (2004) did not detect IFN-␣ protein in lung homogenates taken 24 hr after NP1496 siRNA-PEI polyplex administration. In our experience, both the IFN-␣ and inflammatory cytokine response to lipidic or PEI-complexed siRNA formulations is transient, typically peaking between 2 and 8 hr and fully resolving within 24 hr after administration (Judge and MacLachlan, 2008 ; and data not shown). It is most likely therefore that any assessment of IFN-␣ at a single 24-hr time point will fail to detect this type of response. Our in vivo assessments of IFN induction by NP1496 occurred 6 hr postinjection with siRNA-PEI complexes and a strong induction of IFN-␣ in plasma can be observed at this time point (Fig. 3A) . Functional IFN signaling in the lung was also confirmed by the strong induction of IFN-inducible IFIT1 mRNA that was upregulated more than 30-fold versus vehicle control groups and approximately 6-fold relative to mice treated with unmodified GFP siRNA-PEI complexes (Fig. 3B) . Although we do not exclude the possibility that PEI-complexed anti-influenza siRNA may mediate some degree of RNAi within the infected mouse lung, it is evident from our studies that any specific gene silencing that may be established in this model does not contribute significantly to the observed antiviral response. Further studies designed to detect the specific influenza RNA cleavage products, for example, by performing 5Ј RACE (rapid amplification of cDNA ends) PCR and DNA sequencing (Soutschek et al., 2004) , will be required to confirm the presence or absence of RNAi at subtherapeutic levels. Ultimately, all such in vivo studies need to be conducted in a context in which treatment induces minimal immune stimulation within the target tissue, for example, through the use of 2ЈOMe siRNA, in order to confidently assess RNAi as the primary mechanism of therapeutic action.
